@article{70b1689c63984c5f9385a54f931b9e3b,
title = "Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer's disease",
abstract = "The COVID-19 pandemic has had a profound impact on neuroscientists, including those involved in translational research. In this NeuroView, we discuss the positive and negative effects of the pandemic on preclinical research and clinical studies in humans.",
keywords = "Alzheimer's disease, COVID-19, clinical trials, translational neuroscience",
author = "Snider, {B. Joy} and Holtzman, {David M.}",
note = "Funding Information: D.M.H. is an inventor on a patent licensed by Washington University to C2N Diagnostics and subsequently to AbbVie on the therapeutic use of anti-tau antibodies. D.M.H. is an inventor on a patent licensed by Washington University to Eli Lilly on a humanized anti-amyloid-β antibody. D.M.H. co-founded and is on the scientific advisory board to C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali and Cajal Neurosciences and consults for Genentech, Takeda, and Eli Lilly. The lab of D.M.H. receives research funding to Washington University from C2N Diagnostics, Novartis, and NextCure. B.J.S. is on the Biogen advisory board. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2021",
month = oct,
day = "20",
doi = "10.1016/j.neuron.2021.08.026",
language = "English",
volume = "109",
pages = "3199--3202",
journal = "Neuron",
issn = "0896-6273",
number = "20",
}